

**Ground And Air Medical Transportation Services** 

#### MIEMSS Optional Supplemental Protocols



Presented by: Joshua P. Young NRP March 26, 2016

# Naloxone Optional Supplemental Program



March 26, 2016



• Key Points as listed in the Protocols effective July 1, 2015.







- Indications for administration
  - Patient suffering from Respiratory Depression caused by a known or suspected Opioid/Narcotic overdose.



Contraindications

None clinically significant in Adult patients.

Patients < 28 days old</p>



- Verify prior to administration that
  - ✓Naloxone is in date
  - ✓ Patient meets criteria in protocol for Naloxone administration
  - Should be administered and titrated so respiratory efforts return, but not intended to restore full consciousness.





 Medication supplied in Bristojet packaging 2 mg Naloxone Hydrochloride in 2 ml



- Preparation procedure
  - Open packaging
  - Remove Glass Vial, and Bristojet device
  - Remove cap on end of glass vial
  - Remove cap on end of Bristojet device
  - Gently screw glass vial of medication on Bristojet device

- Preparation continued
  - Attach Mucosal Atomization device to Bristojet



#### Administration Procedure

- Place tip of mucosal atomization device in the nostril and briskly push the plunger forward, administering half of the total volume of medication (up to a MAXIMUM of 1 mL per nostril), occluding opposite nostril.
- Repeat previous step in the other nostril, delivering the remaining half of the medication.





- Post administration
  - Patient should be monitored for response to Naloxone administration.
  - Patients responding to naloxone may require additional doses and transportation to the hospital since most Opioids/Narcotics last longer than Naloxone. Mechanism of action has duration of 40 minutes.

Continued patient management

 Continue supportive care during transport.

Medical consultation required for additional doses to maintain respiratory activity.

